186 related articles for article (PubMed ID: 36252148)
1. Epidemiological and clinical profiles of Saudi patients with hyperprolactinemia in a single tertiary care center.
Mahzari M; Alhamlan KS; Alhussaini NA; Alkathiri TA; Al Khatir AN; Alqahtani AM; Masuadi EF
Ann Saudi Med; 2022; 42(5):334-342. PubMed ID: 36252148
[TBL] [Abstract][Full Text] [Related]
2. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip J; Salvatori R; Yenokyan G; Wand GS
J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
[TBL] [Abstract][Full Text] [Related]
3. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
[TBL] [Abstract][Full Text] [Related]
4. Hyperprolactinemia: a 12-year retrospective study at gynecologic endocrinology unit, Siriraj Hospital.
Saejong R; Dangrat C; Techatrisak K; Angsuwatthana S; Rattanachaiyanont M; Tanmahasamut P
J Med Assoc Thai; 2013 Oct; 96(10):1247-56. PubMed ID: 24350404
[TBL] [Abstract][Full Text] [Related]
5. Clinical and epidemiological characteristics of pituitary tumours in a single centre in Saudi Arabia.
Hussein SH; Wahedi TS; Johani NA; Hakami YA; Alzahrani K; AlMalki MH
Hormones (Athens); 2018 Jun; 17(2):261-267. PubMed ID: 29858852
[TBL] [Abstract][Full Text] [Related]
6. Galactorrhea: Rapid Evidence Review.
Bruehlman RD; Winters S; McKittrick C
Am Fam Physician; 2022 Dec; 106(6):695-700. PubMed ID: 36521467
[TBL] [Abstract][Full Text] [Related]
7. A single- center experience of prolactin-producing pituitary adenomas without hyperprolactinemia: Its incidence and clinical management.
Ogawa Y; Tominaga T
Clin Neurol Neurosurg; 2020 Nov; 198():106123. PubMed ID: 32818756
[TBL] [Abstract][Full Text] [Related]
8. Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.
Almalki MH; Buhary B; Alzahrani S; Alshahrani F; Alsherbeni S; Alhowsawi G; Aljohani N
Pituitary; 2015 Jun; 18(3):405-9. PubMed ID: 25062894
[TBL] [Abstract][Full Text] [Related]
9. True hyperprolactinemia in men without visible pituitary adenoma.
Shimon I; Rudman Y; Manisterski Y; Gorshtein A; Masri H; Duskin-Bitan H
Endocrine; 2021 Jun; 72(3):809-813. PubMed ID: 33566310
[TBL] [Abstract][Full Text] [Related]
10. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
11. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
Arduc A; Gokay F; Isik S; Ozuguz U; Akbaba G; Tutuncu Y; Berker D; Kucukler FK; Aydin Y; Guler S
J Endocrinol Invest; 2015 Apr; 38(4):447-53. PubMed ID: 25421155
[TBL] [Abstract][Full Text] [Related]
12. Frequency of Macroprolactin in Hyperprolactinemia.
Sherazi NA; Baig MZ; Khan AH
J Coll Physicians Surg Pak; 2018 Feb; 28(2):93-97. PubMed ID: 29394965
[TBL] [Abstract][Full Text] [Related]
13. Hyperprolactinemia: pathophysiology and therapeutic approach.
Capozzi A; Scambia G; Pontecorvi A; Lello S
Gynecol Endocrinol; 2015 Jul; 31(7):506-10. PubMed ID: 26291795
[TBL] [Abstract][Full Text] [Related]
14. [Current diagnosis and treatment of hyperprolactinemia].
Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
[TBL] [Abstract][Full Text] [Related]
15. Hyperprolactinemia and impotence: why, when and how to investigate.
Leonard MP; Nickel CJ; Morales A
J Urol; 1989 Oct; 142(4):992-4. PubMed ID: 2795758
[TBL] [Abstract][Full Text] [Related]
16. [Hyperprolactinemia unrelated to prolactinoma].
Krysiak R; Okopień B
Wiad Lek; 2014; 67(2 Pt 1):101-11. PubMed ID: 25764785
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and reproductive manifestations of macroprolactinemia.
Kalsi AK; Halder A; Jain M; Chaturvedi PK; Sharma JB
Endocrine; 2019 Feb; 63(2):332-340. PubMed ID: 30269265
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Laboratory Characteristics of Hyperprolactinemia in Children and Adolescents: National Survey.
Eren E; Törel Ergür A; İşgüven ŞP; Çelebi Bitkin E; Berberoğlu M; Şıklar Z; Baş F; Yel S; Baş S; Söbü E; Bereket A; Turan S; Sağlam H; Atay Z; Ercan O; Güran T; Atabek ME; Korkmaz HA; Kılınç Uğurlu A; Akıncı A; Döğer E; Şimşek E; Akbaş ED; Abacı A; Gül Ü; Acar S; Mengen Uçaktürk E; Yıldız M; Ünal E; Tarım Ö
J Clin Res Pediatr Endocrinol; 2019 May; 11(2):149-156. PubMed ID: 30396878
[TBL] [Abstract][Full Text] [Related]
19. Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.
Vilar L; Naves LA; Freitas MC; Lima M; Canadas V; Albuquerque JL; Lyra R; Azevedo MF; Casulari LA
Minerva Endocrinol; 2007 Jun; 32(2):79-86. PubMed ID: 17557033
[TBL] [Abstract][Full Text] [Related]
20. [Misleading diagnosis of hyperprolactinemia in women].
Paepegaey AC; Veron L; Wimmer MC; Christin-Maitre S
Gynecol Obstet Fertil; 2016 Mar; 44(3):181-6. PubMed ID: 26966035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
